



Berkshire West Area Prescribing Committee

Drug Name	Silicone keloid dressings and silicone gels	
Indication under review	Reduction or prevention of hypertrophic and keloid scarring	
Policy No:	APC 061	
Date of Issue/ Date of reissue:	January 2014/ March 2017	
Review Date:	March 2020	
Policy Statement:	Silicone keloid dressings and silicone gels are not recommended for the reduction or prevention of hypertrophic and keloid scarring due to insufficient evidence of efficacy and cost effectiveness.	
Traffic Light Status	Brown	
Key Points considered:	<ul style="list-style-type: none"> • Weak evidence of any benefit of silicon gel as a prevention for abnormal scarring in high risks individuals and the poor quality of research means a great deal of uncertainty prevails. • Not cost effective. • Cosmetic treatments are not routinely funded on the NHS. 	
References:	<ol style="list-style-type: none"> 1. O'Brien L, Pandit A. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Review. Jan 25 2006. 2. British National Formulary 60. September 2010. 	
Date taken to APC:	1 st March 2017	
Date Ratified by MOC on Behalf of the Board:	15 th March 2017	

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only